Emicizumab for non-severe haemophilia A

被引：0
|
作者：
Makris, Michael [1 ]
机构：
[1] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, England
来源：
LANCET HAEMATOLOGY | 2023年 / 10卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E158 / E159
页数：2
相关论文
共 50 条
  • [1] Inhibitor development in non-severe haemophilia across Europe
    Fischer, Kathelijn
    Iorio, Alfonso
    Lassila, Riitta
    Peyvandi, Flora
    Calizzani, Gabriele
    Gatt, Alex
    Lambert, Thierry
    Windyga, Jerzy
    Gilman, Estelle A.
    Makris, Michael
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (04) : 670 - 675
  • [2] DDAVP trial in discrepant non-severe haemophilia A patients
    Okoye, H. C.
    Nielsen, B. I.
    Lee, K.
    Abajas, Y. L.
    Key, N. S.
    Rollins-Raval, M. A.
    HAEMOPHILIA, 2018, 24 (03) : E152 - E154
  • [3] Inhibitor screening in non-severe haemophilia patients; a major challenge
    Hvas, Anne-Mette
    Poulsen, Lone H.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (05) : 683 - 685
  • [4] Protected by Nature: Effects of Exercise In Non-Severe Haemophilia Patients
    den Uijl, Ingrid E. M.
    Groen, Wim G.
    van der Net, Jan Jaap
    Grobbee, Diederick E.
    de Groot, Philip G.
    Fischer, Kathelijn
    BLOOD, 2010, 116 (21) : 242 - 243
  • [5] Non-severe haemophilia: Is it benign? - Insights from the PROBE study
    Chai-Adisaksopha, Chatree
    Noone, Declan
    Curtis, Randall
    Frick, Neil
    Nichol, Michael B.
    Germini, Federico
    O'Mahony, Brian
    Page, David
    Stonebraker, Jeffrey S.
    Skinner, Mark W.
    Iorio, Alfonso
    HAEMOPHILIA, 2021, 27 : 17 - 24
  • [6] Blue toe syndrome, severe haemophilia A and emicizumab
    Cardoso, Patricia Santos Resende
    da Silva, Camila Beatriz Pereira Gomes
    de Abreu, Eliabe Silva
    Oliveira, Andrea Goncalves
    Pereira, Isabel Figueiredo de Magalhaes
    Navarro, Tulio Pinho
    Rezende, Suely Meireles
    HAEMOPHILIA, 2024, 30 (01) : 241 - 244
  • [7] The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors
    van Velzen, Alice S.
    Eckhardt, Corien L.
    Streefkerk, Nina
    Peters, Marjolein
    Hart, Daniel P.
    Hamulyak, Karly
    Klamroth, Robert
    Meijer, Karina
    Nijziel, Marten
    Schinco, Piercarla
    Yee, Thynn T.
    van der Bom, Johanna G.
    Fijnvandraat, Karin
    THROMBOSIS AND HAEMOSTASIS, 2016, 115 (03) : 543 - 550
  • [8] A large-scale computational study of inhibitor risk in non-severe haemophilia A
    Shepherd, Adrian J.
    Skelton, Stuart
    Sansom, Clare E.
    Gomez, Keith
    Moss, David S.
    Hart, Daniel P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (03) : 413 - 420
  • [9] FACTOR VIII LEVELS IN BLOOD GROUP O AND NON-O IN NON-SEVERE HAEMOPHILIA A
    Rejto, J.
    Koenigsbruegge, O.
    Grilz, E.
    Hofer, S.
    Gebhart, J.
    Schuster, G.
    Feistritzer, C.
    Quehenberger, P.
    Ay, C.
    Pabinger, I.
    HAEMOPHILIA, 2020, 26 : 35 - 36
  • [10] In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies
    Behnaz Pezeshkpoor
    M. Gazorpak
    A-C. Berkemeier
    H. Singer
    A. Pavlova
    A. Biswas
    J. Oldenburg
    Annals of Hematology, 2019, 98 : 1855 - 1865
12345